Cargando…
Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequenci...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349109/ https://www.ncbi.nlm.nih.gov/pubmed/37452081 http://dx.doi.org/10.1038/s42003-023-05094-5 |
_version_ | 1785073828061249536 |
---|---|
author | Zhou, Mengchen Yao, Yan Wang, Xiangyi Zha, Lingfeng Chen, Yilin Li, Yanze Wang, Mengru Yu, Chenguang Zhou, Yingchao Li, Qianqian Cao, Zhubing Wu, Jianfei Shi, Shumei Jiang, Dan Long, Deyong Wang, Jiangang Wang, Qing Cheng, Xiang Liao, Yuhua Tu, Xin |
author_facet | Zhou, Mengchen Yao, Yan Wang, Xiangyi Zha, Lingfeng Chen, Yilin Li, Yanze Wang, Mengru Yu, Chenguang Zhou, Yingchao Li, Qianqian Cao, Zhubing Wu, Jianfei Shi, Shumei Jiang, Dan Long, Deyong Wang, Jiangang Wang, Qing Cheng, Xiang Liao, Yuhua Tu, Xin |
author_sort | Zhou, Mengchen |
collection | PubMed |
description | Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequencing (WES) and Sanger sequencing. RNA-seq and function experiments show the reduction of the expression of KIF1C and PRKAR1A caused by rare variations of KIF1C. KIF1C is observed to be located in the nucleus, bind to the promoter region of PRKAR1A, and regulate its transcription. Reduction of KIF1C decreases PRKAR1A expression and activates the PKA, which causes an increase in ERK1/2 phosphorylation and SRC-mediated STAT3 activation, a reduction of CDH1, TP53, CDKN1A, and BAX, and eventually promotes tumor formation both in vitro and in vivo. The results suggest that inhibition of KIF1C promotes the pathogenesis of LAM through positive feedback formed by the crosstalk between KIF1C and PRKAR1A. |
format | Online Article Text |
id | pubmed-10349109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103491092023-07-16 Crosstalk between KIF1C and PRKAR1A in left atrial myxoma Zhou, Mengchen Yao, Yan Wang, Xiangyi Zha, Lingfeng Chen, Yilin Li, Yanze Wang, Mengru Yu, Chenguang Zhou, Yingchao Li, Qianqian Cao, Zhubing Wu, Jianfei Shi, Shumei Jiang, Dan Long, Deyong Wang, Jiangang Wang, Qing Cheng, Xiang Liao, Yuhua Tu, Xin Commun Biol Article Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequencing (WES) and Sanger sequencing. RNA-seq and function experiments show the reduction of the expression of KIF1C and PRKAR1A caused by rare variations of KIF1C. KIF1C is observed to be located in the nucleus, bind to the promoter region of PRKAR1A, and regulate its transcription. Reduction of KIF1C decreases PRKAR1A expression and activates the PKA, which causes an increase in ERK1/2 phosphorylation and SRC-mediated STAT3 activation, a reduction of CDH1, TP53, CDKN1A, and BAX, and eventually promotes tumor formation both in vitro and in vivo. The results suggest that inhibition of KIF1C promotes the pathogenesis of LAM through positive feedback formed by the crosstalk between KIF1C and PRKAR1A. Nature Publishing Group UK 2023-07-14 /pmc/articles/PMC10349109/ /pubmed/37452081 http://dx.doi.org/10.1038/s42003-023-05094-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhou, Mengchen Yao, Yan Wang, Xiangyi Zha, Lingfeng Chen, Yilin Li, Yanze Wang, Mengru Yu, Chenguang Zhou, Yingchao Li, Qianqian Cao, Zhubing Wu, Jianfei Shi, Shumei Jiang, Dan Long, Deyong Wang, Jiangang Wang, Qing Cheng, Xiang Liao, Yuhua Tu, Xin Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title | Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title_full | Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title_fullStr | Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title_full_unstemmed | Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title_short | Crosstalk between KIF1C and PRKAR1A in left atrial myxoma |
title_sort | crosstalk between kif1c and prkar1a in left atrial myxoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349109/ https://www.ncbi.nlm.nih.gov/pubmed/37452081 http://dx.doi.org/10.1038/s42003-023-05094-5 |
work_keys_str_mv | AT zhoumengchen crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT yaoyan crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT wangxiangyi crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT zhalingfeng crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT chenyilin crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT liyanze crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT wangmengru crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT yuchenguang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT zhouyingchao crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT liqianqian crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT caozhubing crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT wujianfei crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT shishumei crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT jiangdan crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT longdeyong crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT wangjiangang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT wangqing crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT chengxiang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT liaoyuhua crosstalkbetweenkif1candprkar1ainleftatrialmyxoma AT tuxin crosstalkbetweenkif1candprkar1ainleftatrialmyxoma |